Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NeoTherapeutics Alzheimer's therapy AIT-082 could enter Phase I through NIH by year-end.

Executive Summary

NEOTHERAPEUTICS AIT-082 COULD ENTER PHASE I FOR ALZHEIMER's BY YEAR END under the auspices of the National Institute on Aging's Alzheimer's Disease Cooperative Study Unit, according to a prospectus for NeoTherapeutics' initial public offering. NIA "has committed to fund and conduct two Phase I clinical trials" and is funding, with the National Institute for Mental Health, production of AIT-082 for clinical trials, the prospectus states.



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts